Difficulties in the treatment of recurring diffuse alveolar hemorrhage accompanying primary antiphospholipid syndrome: a case report and literature review

Adv Respir Med. 2018;86(3). doi: 10.5603/ARM.2018.0020.

Abstract

Pulmonary embolism is the most common pulmonary manifestation of primary antiphospholipid syndrome (PAPS). However, PAPS may manifest in the respiratory system also due to non-thrombotic processes. In the following paper we present a case of PAPS-related diffuse alveolar hemorrhage (DAH). Because of sparse literature and a lack of randomized controlled trials, there are currently no recommendations regarding the optimal choice of steroid-sparing agent in treating PAPS-related DAH. In our patient, treatment with cyclophosphamide or mycophenolate mofetil along with low dose prednisone was ineffective, partially because of infectious complications, whereas addition of monthly intravenous immunoglobulin to mycophenolate mofetil and prednisone, appears to control the disease.

Keywords: antiphospholipid syndrome; capillaries; cyclophosphamide; hemorrhage; immunoglobulins; immunosuppressive agents; intravenous; lung diseases; mycophenolic acid; prednisone.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Antiphospholipid Syndrome / complications*
  • Antiphospholipid Syndrome / etiology
  • Hemorrhage / etiology*
  • Humans
  • Male
  • Pulmonary Embolism / complications*